Blog

Evaluating molecularly guided therapies beyond tumor type – ESMO

Photo of Benedikt Westphalen taken from LinkedIn

Feb 20, 2025, 10:45

Evaluating molecularly guided therapies beyond tumor type – ESMO

ESMO shared a post on X:

“The ESMO Tumor-Agnostic Classifier and Screener (ETAC-S) introduces a framework for evaluating molecularly guided therapies beyond tumor type.

Where does Liquid Biopsy fit in?

Enables non-invasive genomic profiling for tumor-agnostic therapies

Detects targetable alterations in ctDNA for real-time treatment decisions

Supports longitudinal monitoring of treatment response and resistance.

Liquid biopsy is shaping the future of molecular screening and tumor-agnostic precision oncology!

Learn more.”

The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

Authors: C.B. Westphalen et al.

molecularly guided therapies

A. Marabelle A.M. Schram C. Cardone C. Marchió C. Yap C.B. Westphalen cancer D. Martins Branco E. Garralda F. André F. Bibeau G Curigliano G Pentheroudakis J. Mateo J. Rodon J.R. Beal N. Coleman OncoDaily Oncology R. Kurzrock S. Halabi S. Kummar S. Limaye S. Loges S. Michiels T. Spanic V Subbiah

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology